PTI 428

Drug Profile

PTI 428

Alternative Names: PTI-428

Latest Information Update: 21 Oct 2016

Price : $50

At a glance

  • Originator Proteostasis Therapeutics
  • Class Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Cystic fibrosis
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cystic fibrosis

Highest Development Phases

  • Phase I Cystic fibrosis

Most Recent Events

  • 11 Aug 2016 Preliminary pharmacokinetics data from a phase I trial in Healthy volunteers released by Proteostasis Therapeutics
  • 01 Jun 2016 Proteostasis Therapeutics initiates a phase I trial in Healthy volunteers in USA (PO) (NCT02846142)
  • 10 May 2016 Proteostasis Therapeutics has patents pending for PTI 428 in USA and with the patent cooperation treaty (Proteostasis Therapeutics 10-K; march 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top